Evidence map›Paper›PMID 29867983›Full record

ArticleFrontiers in immunology2018

IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction.

Nicholas J W Easom, Kerstin A Stegmann, Leo Swadling, Laura J Pallett, Alice R Burton, Dennis Odera, Nathalie Schmidt, Wei-Chen Huang, Giuseppe Fusai, Brian Davidson and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 94 citations in OpenAlex.

  1. Trial
  2. Increased Frequency of Dysfunctional Siglec-7Frontiers in immunology · 2021
    Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Immunotherapy for hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2024
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Nicholas J W EasomDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Kerstin A StegmannDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Leo SwadlingDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Laura J PallettDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Alice R BurtonDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Dennis OderaDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Nathalie SchmidtDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Wei-Chen HuangDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Giuseppe FusaiCentre for Digestive Diseases, Institute of Liver and Digestive Health, University College London, London, United Kingdom.
Brian DavidsonCentre for Digestive Diseases, Institute of Liver and Digestive Health, University College London, London, United Kingdom.
Mala K MainiDivision of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.
University College London · GBTri-Service General Hospital · TW

Funding

Medical Research Council MR/M020126/1MRF_ MRF-044-0001-RG-SWADLWellcome Trust 101849/Z/13/ZWellcome Trust 102772/Z/13/Z
6 · The paper itself

Abstract

NK cells have potent antitumor capacity. They are enriched in the human liver, with a large subset specialized for tissue-residence. The potential for liver-resident versus liver-infiltrating NK cells to populate, and exert antitumor functions in, human liver tumors has not been studied. We examined liver-resident and liver-infiltrating NK cells directly

Indexed as

Carcinoma, HepatocellularCell Line, TumorCell MovementCoculture TechniquesCytokinesCytotoxicity, ImmunologicDown-RegulationHumansImmunotherapyInterleukin-15Killer Cells, NaturalLiver NeoplasmsNK Cell Lectin-Like Receptor Subfamily KSignal TransductionCytokinesIL15 protein, humanInterleukin-15KLRK1 protein, humanNK Cell Lectin-Like Receptor Subfamily Khepatocellular carcinomaIL-15immunotherapyliver tumorsNK cellsNKG2Dtissue-resident NK cellstumor escape

Identifiers

PMID29867983
PMCPMC5954038
OpenAlexW2801582151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.